---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-308769"
form_type: "8-K"
ticker: "TRVI"
cik: "0001563880"
company_name: "Trevi Therapeutics, Inc."
filed_at: "2025-12-05T23:59:59+00:00"
generated_at: "2026-05-16T14:14:56.207227+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Trevi Therapeutics appoints David Hastings as CFO effective January 6, 2026

## Summary
- David Hastings previously served as CFO of Arbutus Biopharma (June 2018–March 2025).
- Base salary set at $522,000; annual bonus target up to 40% of base salary.
- Receives option to purchase 375,000 shares, vesting 25% on first anniversary and monthly thereafter.
- Eligible for separation benefits under the Executive Separation Benefits and Retention Plan.
- Standard indemnification agreement to be entered with the company.

## SEC filing metadata
- accession: 0001193125-25-308769
- form_type: 8-K
- ticker: TRVI
- cik: 0001563880
- company_name: Trevi Therapeutics, Inc.
- filed_at: 2025-12-05T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1563880/000119312525308769/0001193125-25-308769-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1563880/000119312525308769/trvi-20251201.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-308769
- JSON: https://secwatch.observer/filing/0001193125-25-308769.json
- Plain text: https://secwatch.observer/filing/0001193125-25-308769.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.